Latest Headlines

Latest Headlines

FDA maintains tight grip on Indian and Chinese products

The U.S. Food and Drug Administration rejected more than 13,000 products made in India in the 5 years between 2010 and 2015, according to FDA data cited in an Economic Times report, and rejected slightly more than 15,000 products made in China.

American pharma group says IP protection in India is weak

The Pharmaceutical Research and Manufacturers of America (PhRMA), one of the top bodies representing American pharmaceutical and biotechnology companies, said in its annual report that India's intellectual property rights protection is weak and the group added India to its "priority watch list."

Indian hospitals pioneering use of 'eICUs' to combat doctor shortage

Indian doctors recently saved the life of a 30-year-old woman by instructing an unspecialized doctor about chest compressions over Internet-enabled video. The country's private hospital chains such as Fortis and Apollo plan to expand the number of so-called eICU beds by about 20% a year, from about 3,000 beds right now.

Japan continues to see generics as way to ease healthcare costs

The government of Japan is changing the lucrative brand-name healthcare market as its population ages and requires more drugs with a push to make at least 80% of the government's drug spending be for generics.

Japan's Eisai surprises with API move

Tokyo-based Eisai said it will start selling active pharmaceutical ingredients to domestic generic makers and will invest "tens of millions of dollars" to scale up production at its India plant in Andhra Pradesh. 

GSK's CEO says it's 'difficult to understand how company is doing'

GlaxoSmithKline's CEO Andrew Witty, who has been accused by major investors of "not doing a very good job" and is in the crosshairs of hedge funds, said in a recent interview in India that it is "difficult to understand how the company is doing because so much has changed."

India's Sun Pharmaceutical meets Feb. 1 deadline for U.S. imatinib launch

Mumbai-based Sun Pharmaceutical Industries met an in-house deadline of Feb. 1 to launch sales of generic Gleevec/Glivec (imatinib) in the U.S. that included a savings card program to cut the co-payment out-of-pocket costs for the cancer treatment with certain pharmacies.

FDA hands Wockhardt and Ipca more disappointing news

It has been another tough week for some of India's troubled drugmakers. Wockhardt, which has two plants banned by the FDA, saw its hopes stymied for getting export approval for a different facility that it had hoped could help it recoup some of its lost U.S. revenues. And India's Ipca Laboratories, which has three plants on the import alert list, said Monday it has now gotten a warning letter for the facilities.

India's patent office nixes Takeda diabetes application

The patent office in India has slapped down an application from Tokyo-based Takeda Pharmaceutical for its single-dose Type 2 diabetes treatment dipeptidyl peptidase 4 (DPP-4) inhibitor.

Novartis expects India's Sun to meet February U.S. generic Gleevec launch

Switzerland-based Novartis sees Mumbai-based Sun Pharmaceutical Industries meeting its February target start date for sales of generic Gleevec/Glivec (imatinib), putting the Indian drugmaker in the spotlight on the deadline.